Latest Breaking News On - Charlesm rudin - Page 1 : vimarsana.com

CHICAGO Adding tiragolumab, an anti-TIGIT agent, to atezolizumab and carboplatin plus etoposide did not provide more benefit compared with atezolizumab and carboplatin plus etoposide alone, according to findings from SKYSCRAPER-02 trial. “The IMpower130 trial defined a new standard of care for the treatment of extensive-stage small cell lung cancer, demonstrating a benefit for the addition of the PD-L1 inhibitor atezolizumab to a backbone of carboplatin and etoposide for the treatment of extensive-stage small cell lung cancer,” Charles M. Rudin, MD, chief of thoracic oncology at Memorial Sloan Kettering Cancer Center, said during his presentation at ASCO Annual Meeting. “Although this was a clinical advance, the vast majority of patients with extensive-stage small cell lung cancer continue to suffer disease progression with a median of about 5 and a half months from the time of diagnosis. So, there is clearly a major unmet need for the treatment of these patients.”

United statesCharlesm rudinRoche genentechGenentech rocheMarleyv ghizzoneSyros pharmaceuticalsJazz pharmaceuticalsMemorial sloan kettering cancer centerBridge medicinesHarpoon therapeutics